Adaptimmune Therapeutics plc (ADAP) financial statements (2022 and earlier)

Company profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments369,580368,21789,542205,134208,261158,779
Cash and cash equivalents149,94856,88250,41268,37984,043158,779
Short-term investments219,632311,33539,130136,755124,218 
Receivables34,00720,72420,67118,15611,6601,480
Prepaid expense9,0436,3148,3956,2796,120 
Other current assets2,082811422439382 
Other undisclosed current assets7462,0861,4591,0873,76038,492
Total current assets:415,458398,152120,489231,095230,183198,751
Noncurrent Assets
Operating lease, right-of-use asset20,87518,88020,789
Property, plant and equipment30,49427,77831,06836,11840,67927,899
Intangible assets, net (including goodwill)1,0001,7302,1981,4731,3371,268
Intangible assets, net (excluding goodwill)1,0001,7302,1981,4731,3371,268
Restricted cash and investments1,7184,6024,4964,0974,2534,017
Other undisclosed noncurrent assets  2,5033,9534,6952,580
Total noncurrent assets:54,08752,99061,05445,64150,96435,764
TOTAL ASSETS:469,545451,142181,543276,736281,147234,515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38,02233,46829,72014,05818,91415,889
Accounts payable8,1136,3896,3574,0838,37811,350
Accrued liabilities29,90927,07923,3632,4223,944 
Employee-related liabilities   7,5536,5924,539
Deferred revenue22,1992,8322,128
Debt  2,493   
Due to related parties    32639
Deferred revenue and credits38,73511,392
Other liabilities   3163571,080
Other undisclosed current liabilities2,3202,773 10,06315,98211,870
Total current liabilities:62,54139,07334,34124,43774,31440,270
Noncurrent Liabilities
Long-term debt and lease obligation23,14820,93822,966   
Operating lease, liability23,14820,93822,966
Liabilities, other than long-term debt177,89649,9045985,4143,84924,962
Deferred revenue and credits 24,962
Deferred revenue177,22349,260 
Other liabilities6736445985,4143,849 
Other undisclosed noncurrent liabilities     3,141
Total noncurrent liabilities:201,04470,84223,5645,4143,84928,103
Total liabilities:263,585109,91557,90529,85178,16368,373
Stockholders' equity
Stockholders' equity attributable to parent205,960341,227123,638246,885202,984166,142
Common stock1,3371,325943939854683
Additional paid in capital959,611935,706585,623574,208455,401341,200
Accumulated other comprehensive loss(11,142)(10,048)(7,264)(9,763)(21,641)(14,249)
Accumulated deficit(743,846)(585,756)(455,664)(318,499)(231,630)(161,492)
Total stockholders' equity:205,960341,227123,638246,885202,984166,142
TOTAL LIABILITIES AND EQUITY:469,545451,142181,543276,736281,147234,515

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues6,1493,9581,12259,50537,83314,198
Revenue, net37,83314,198
Gross profit:6,1493,9581,12259,50537,83314,198
Operating expenses(168,395)(137,363)(140,892)(141,870)(118,494)(86,997)
Operating loss:(162,246)(133,405)(139,770)(82,365)(80,661)(72,799)
Nonoperating income (expense)3,8521,1622,847(12,652)10,9741,002
Investment income, nonoperating  2,7722,8492,230 
Other nonoperating income (expense)3,8521,16275(15,501)8,7441,002
Loss from continuing operations before equity method investments, income taxes:(158,394)(132,243)(136,923)(95,017)(69,687)(71,797)
Other undisclosed income from continuing operations before income taxes1,0952,313   1,110
Loss from continuing operations before income taxes:(157,299)(129,930)(136,923)(95,017)(69,687)(70,687)
Income tax expense(791)(162)(242)(497)(451)(892)
Net loss available to common stockholders, diluted:(158,090)(130,092)(137,165)(95,514)(70,138)(71,579)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(158,090)(130,092)(137,165)(95,514)(70,138)(71,579)
Comprehensive loss:(158,090)(130,092)(137,165)(95,514)(70,138)(71,579)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,094)(2,784)2,49911,878(7,392)(6,110)
Comprehensive loss, net of tax, attributable to parent:(159,184)(132,876)(134,666)(83,636)(77,530)(77,689)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: